- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT01075412
FLT PET Imaging for Cervical Cancer
'F-18 Fluorothymidine ([18F]FLT) PET Imaging for Early Evaluation of Response to Chemoradiation Therapy in Patients With Cervical Cancer
Our primary hypothesis is that [18F]FLT PET can identify active bone marrow in addition to metabolically active tumor.
This trial will use FLT-PET imaging to define areas of active bone marrow in the pelvis. The radiation plan is then designed to spare that area, in hopes of keeping the bone marrow active during therapy. Bone marrow and tumor activity will be monitored using a sequence of FLT PET scans during the course of chemotherapy and radiation therapy.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Subjects will undergo a total of up to 5 FLT PET scans.
Subjects are randomized between two groups to reduce radiation exposure from the FLT PET scans. If bone marrow activity is not identified in one scan, further scans are cancelled until the 1-month follow up scan. This is not a randomization to compare therapeutic efficacy between two study arms. Data will be pooled for analysis as pre-specified in the study's statistical plan.
Group 1 has FLT PET scans pretreatment, after 5 radiation treatments, after 10 radiation treatments, after 15 radiation treatments, and then 1 month after completing radiation therapy.
Group 2 has FLT PET scans pretreatment, after 5 radiation treatments, after 10 radiation treatments, after 20 radiation treatments, and then 1 month after completing radiation therapy.
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 2
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Iowa
-
Iowa City, Iowa, Estados Unidos, 52242
- Holden Comprehensive Cancer Center
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Ability to understand and willingness to sign a written informed consent document.
- Histologically confirmed stage IB2, IIA, IIB, IIIB, and IVA squamous cell carcinoma of the cervix.
- Scheduled to receive chemo-radiation for oncologic treatment.
- Karnofsky of at least 60 at time of screening
- Life expectancy of at least 6 months.
- Leukocytes at least 3,000/microL
- absolute neutrophil count at least 1,500/microL
- platelets at least 100,000/microL
- total bilirubin at maximum 1.0 mg/dL (UIHC limit of normal)
- either ALT or AST less than 2.5 times the upper limit of normal
- creatinine less than 1.5 times the upper limit of normal
- non-pregnant, non-nursing, willing to use contraception
Exclusion Criteria:
- oncology research protocol requiring full pelvic radiation (i.e., 4-field box technique) or experimental chemotherapy
- uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with the study requirements.
- subjects taking nucleoside analog medications such as those used as antiretroviral agents.
- patients who have undergone hysterectomy or will have a hysterectomy as part of their cancer therapy.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: Group 2
Receives fourth [F18]Fluorothymidine (FLT) PET scan after 20 fractions of radiation therapy.
|
FLT PET scan 5 mCi (+/- 10%)
Otros nombres:
|
Experimental: Group 1
Receives fourth [F18]Fluorothymidine (FLT) PET scan after 15 fractions of radiation therapy.
|
FLT PET scan 5 mCi (+/- 10%)
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Percent Difference From Baseline IMRT Plan (%)
Periodo de tiempo: Baseline (pre-treatment)
|
The difference in volume of bone marrow receiving radiation using a bone-marrow-sparing radiation plan compared to a standard radiation plan (IMRT), expressed as a percentage.
Both plans are patient-specific.
Bone-marrow is identified using the baseline FLT PET/CT obtained pre-imaging.
Active bone marrow is considered to have an uptake value (SUV) of 2, 3, or 4. The standard IMRT plan was created using the criteria of the National Cancer Institute's Radiation Therapy Oncology Group study RTOG-0418.
Radiation dose bins evaluated are 5 Gray, 10 Gray, 20 Gray, and 30 Gray.
The change in dose to tumor is also provided.
A negative value indicates that more bone marrow or tissue was spared using the bone-marrow sparing plan.
|
Baseline (pre-treatment)
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Chemotherapy Compliance
Periodo de tiempo: post-treatment
|
The number of participants who missed at least one prescribed chemotherapy administration due to low blood counts.
|
post-treatment
|
Number of Participants With Standardized Toxicity Severity Grades for White Blood Cell Counts
Periodo de tiempo: baseline, weekly during radiation treatment for up to 5 weeks, and 30 days post treatment
|
White blood cell counts measurements expressed in standardized toxicity severity grades (Common Terminology Criteria for Adverse Events, v4.03) measured weekly during combined chemotherapy and radiation therapy treatment and then once at 30 day follow-up and at 1 year follow-up
|
baseline, weekly during radiation treatment for up to 5 weeks, and 30 days post treatment
|
Number of Participants With Standardized Toxicity Severity Grades for Decreased Platelet Counts.
Periodo de tiempo: baseline, weekly during radiation treatment for up to 5 weeks, and 30 days post treatment
|
Platelet cell counts measurements expressed in standardized toxicity severity grades (Common Terminology Criteria for Adverse Events, v4.03) measured once weekly during combined chemotherapy and radiation therapy, then once at 30 day follow-up, and once at 1 year follow-up
|
baseline, weekly during radiation treatment for up to 5 weeks, and 30 days post treatment
|
Number of Participants With Standardized Toxicity Severity Grades for Decreased Absolute Neutrophil Counts (ANCs)
Periodo de tiempo: baseline, weekly during radiation treatment for up to 5 weeks, and 30 days post treatment
|
Absolute neutrophil counts (ANCs) measurements expressed in standardized toxicity severity grades (Common Terminology Criteria for Adverse Events, v4.03) measured once weekly during combined chemotherapy and radiation therapy, then once at 30 day follow-up, and once at 1 year follow-up.
|
baseline, weekly during radiation treatment for up to 5 weeks, and 30 days post treatment
|
Number of Participants With Standardized Toxicity Severity Grades for Decreased Lymphocyte Counts.
Periodo de tiempo: baseline, weekly during radiation treatment for up to 5 weeks, and 30 days post treatment
|
Lymphocyte counts measurements expressed in standardized toxicity severity grades (Common Terminology Criteria for Adverse Events, v4.03) measured once weekly during combined chemotherapy and radiation therapy, then once at 30 day follow-up, and once at 1 year follow-up
|
baseline, weekly during radiation treatment for up to 5 weeks, and 30 days post treatment
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Director de estudio: Michael M Graham, Ph.D., M.D., University of Iowa
- Investigador principal: Sarah McGuire, Ph.D., University of Iowa
Publicaciones y enlaces útiles
Publicaciones Generales
- McGuire SM, Menda Y, Ponto LL, Gross B, Juweid M, Bayouth JE. A methodology for incorporating functional bone marrow sparing in IMRT planning for pelvic radiation therapy. Radiother Oncol. 2011 Apr;99(1):49-54. doi: 10.1016/j.radonc.2011.01.025. Epub 2011 Mar 22.
- McGuire SM, Menda Y, Boles Ponto LL, Gross B, Buatti J, Bayouth JE. 3'-deoxy-3'-[(1)(8)F]fluorothymidine PET quantification of bone marrow response to radiation dose. Int J Radiat Oncol Biol Phys. 2011 Nov 1;81(3):888-93. doi: 10.1016/j.ijrobp.2010.12.009. Epub 2011 Feb 6. Erratum In: Int J Radiat Oncol Biol Phys. 2012 Sep 1;84(1):7.
- Menda Y, Ponto LL, Dornfeld KJ, Tewson TJ, Watkins GL, Gupta AK, Anderson C, McGuire S, Schultz MK, Sunderland JJ, Graham MM, Buatti JM. Investigation of the pharmacokinetics of 3'-deoxy-3'-[18F]fluorothymidine uptake in the bone marrow before and early after initiation of chemoradiation therapy in head and neck cancer. Nucl Med Biol. 2010 May;37(4):433-8. doi: 10.1016/j.nucmedbio.2010.02.005.
- McGuire SM, Bhatia SK, Sun W, Jacobson GM, Menda Y, Ponto LL, Smith BJ, Gross BA, Bayouth JE, Sunderland JJ, Graham MM, Buatti JM. Using [(18)F]Fluorothymidine Imaged With Positron Emission Tomography to Quantify and Reduce Hematologic Toxicity Due to Chemoradiation Therapy for Pelvic Cancer Patients. Int J Radiat Oncol Biol Phys. 2016 Sep 1;96(1):228-39. doi: 10.1016/j.ijrobp.2016.04.009. Epub 2016 Apr 19.
- McGuire SM, Menda Y, Ponto LLB, Gross B, TenNapel M, Smith BJ, Bayouth JE. Spatial mapping of functional pelvic bone marrow using FLT PET. J Appl Clin Med Phys. 2014 Jul 8;15(4):129-136. doi: 10.1120/jacmp.v15i4.4780.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 200906786
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Neoplasias del cuello uterino
-
Stanford UniversityTerminadoCirugía Cervical Posterior | Fusión cervical posterior | Laminectomía cervical posterior | Laminoplastia Cervical PosteriorEstados Unidos
-
Gazi UniversityReclutamientoRadiculopatía cervical | Dolor radicular cervical | Radiculitis cervical | Síndrome de la raíz cervicalPavo
-
Blaz BarunReclutamientoLesión por latigazo cervical de la columna cervicalCroacia
-
University of IcelandLandspitali University Hospital; Reykjavik University; Empowered HealthActivo, no reclutandoLesión por latigazo cervical de la columna cervicalIslandia
-
Valérie SchuermansReclutamientoEnfermedad del disco cervical | Fusión cervical | Fusión de columna | Espondilosis cervical | Hernia de disco cervical | Mielopatía cervical | Degeneración del disco cervical | Radiculopatía Cervical | Mielopatía Compresiva | Radiculopatía, Región Cervical | Radiculopatía; en espondilosis | Radiculopatía; en... y otras condicionesPaíses Bajos
-
Istanbul Medipol University HospitalTerminadoDolor | Radiculopatía cervical | Enfermedad del disco cervical | Hernia de disco cervical | Dolor radicular cervical | Cervical; HerniaPavo
-
NuVasiveInscripción por invitaciónRadiculopatía cervical | Enfermedad del disco cervical | Enfermedad de la columna cervical | Mielopatía cervical | Espondilosis cervical | Hernia de disco cervical | Estenosis cervicalEstados Unidos
-
University of MichiganWashington University School of Medicine; LFR InternationalTerminadoLesión de la vértebra cervical | Fractura de vértebra cervicalEstados Unidos
-
Western Galilee Hospital-NahariyaReclutamiento
-
Imperial College Healthcare NHS TrustImperial College London; The Wellington Hospital, LondonTerminado
Ensayos clínicos sobre [F18]Fluorothymidine
-
Johns Hopkins UniversityNational Institute on Aging (NIA)RetiradoSaludable | Enfermedad de AlzheimerEstados Unidos
-
Siemens Molecular ImagingTerminadoCáncer de mamaEstados Unidos
-
Assistance Publique Hopitaux De MarseilleDesconocido
-
Avid RadiopharmaceuticalsTerminadoEnfermedad de alzheimerEstados Unidos
-
Avid RadiopharmaceuticalsTerminadoDegeneración corticobasal | Parálisis Supranuclear ProgresivaEstados Unidos
-
Chang Gung Memorial HospitalDesconocido
-
Lantheus Medical ImagingRetiradoEnfermedad de la arteria coronaria
-
National Cancer Institute (NCI)Reclutamiento
-
Eli Lilly and CompanyAún no reclutandoEnfermedad de AlzheimerEstados Unidos, Reino Unido, Japón
-
Radboud University Medical CenterABX advanced biochemical compounds GmbH; Radboud Translational MedicineReclutamientoCáncer de próstata recurrentePaíses Bajos